Scheen AJ. Cardiovascular Risk-Benefit Profile of Sibutramine. Am J Cardiovasc Drugs 2010;10:321-334
James WP, Caterson ID, Coutinho W, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med 2010;363:905-917
Harrison-Woolrych M, Ashton J, Herbison P. Fatal and Non-Fatal Cardiovascular Events in a General Popula- tion Prescribed Sibutramine in New Zealand. Drug Saf 2010;33:605-613
Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardio- vascular Causes. N Engl J Med 2007;356:2457-2471
Nissen SE, Wolski K. Rosiglitazone Revisited: An updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010;170:1191-1201
Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combi- nation therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009;373:2125-2135
US Food and Drug Administration. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/Guidance CompliacneRegulatoryInformation/Guidances/UCM 071627.pdf